RNA

Cas9 mRNA (5'CAP) is a DNA endonuclease mRNA produced by in vitro transcription. It has a Cap 1 cap structure and a poly(A) tail.

Cas9 mRNA with N1-Me-pUTP (5'CAP) is a DNA endonuclease mRNA produced by in vitro transcription. It has a Cap 1 cap structure and a poly(A) tail, and contains N1-Me-pUTP modification.

Cy5 Cas9 mRNA (5'CAP) is produced through in vitro transcription. By simulating the mRNA processing process in eukaryotes, Cy5 Cas9 mRNA (5'CAP) has a 5 'end Cap 1 cap structure, a 3' end poly (A) tail, and Cy5-UTP modification (Cy5-UTP: UTP=3:1 (molar ratio)), which increases the stability and translation efficiency of mRNA.

Cy5 Cas9 mRNA with N1-Me-pUTP (5'CAP) is produced through in vitro transcription. By simulating the mRNA processing process in eukaryotes, Cy5 Cas9 mRNA with N1-Me-pUTP (5'CAP) has a 5 'end Cap 1 cap structure, a 3' end poly (A) tail, Cy5-UTP modification, and N1-Me-pUTP modification (Cy5-UTP: N1-Me-pUTP=3:1 (molar ratio)), which increases the stability and translation efficiency of mRNA.

Cy5 eGFP mRNA with N1-Me-pUTP (5'CAP) is a green fluorescent protein mRNA transcribed in vitro by simulating mRNA processing in eukaryotes. Cy5 eGFP mRNA with N1-Me-pUTP (5’CAP) carries Cy5-UTP modification, N1-Me-pUTP modification (Cy5-UTP: N1-Me-pUTP=3:1 (molar ratio)), Cap 1 cap structure, and poly (A) tail, increasing mRNA stability and translation efficiency.

Cy5 eGFP mRNA (5'CAP) is a green fluorescent protein mRNA transcribed in vitro by simulating mRNA processing in eukaryotes. Cy5 eGFP mRNA (5'CAP) carries Cy5 labeling(Cy5-UTP: UTP=3:1 (molar ratio)), Cap 1 cap structure, and poly (A) tail, which can effectively inhibit RNA mediated innate immune activation.

Cy5 Fluc mRNA with N1-Me-pUTP (5'CAP) is a luciferase mRNA transcribed in vitro by simulating mRNA processing in eukaryotes. Cy5 Fluc mRNA with N1-Me-pUTP (5'CAP) carries Cy5-UTP modification, N1-Me-pUTP modification (Cy5-UTP: N1-Me-pUTP=3:1 (molar ratio)), Cap 1 cap structure, and poly (A) tail, which enhances mRNA stability and translation efficiency.

Cy5 Fluc mRNA (5'CAP) is a luciferase mRNA transcribed in vitro by simulating mRNA processing in eukaryotes. Cy5 Fluc mRNA (5'CAP) carries the Cy5 label (Cy5-UTP:UTP=3:1 (molar ratio)), Cap 1 cap structure, and poly (A) tail, and can effectively inhibit RNA mediated innate immune activation.

Cy5 Fluc-eGFP mRNA with N1-Me-pUTP (5'CAP) is a luciferase green fluorescent protein mRNA transcribed in vitro by simulating mRNA processing in eukaryotes. Cy5 Fluc-eGFP mRNA with N1-Me-pUTP(5’CAP) carries Cy5-UTP modification, N1-Me-pUTP modification (Cy5-UTP: N1-Me-pUTP=3:1 (molar ratio)), Cap 1 cap structure, and poly (A) tail, increasing mRNA stability and translation efficiency.

Cy5 Fluc-eGFP mRNA (5'CAP) is a labeled luciferase green fluorescent protein mRNA transcribed in vitro by simulating mRNA processing in eukaryotes. Cy5 Fluc-eGFP mRNA (5'CAP) carries the Cy5 label(Cy5-UTP: UTP=3:1 (molar ratio)), Cap 1 cap structure, and poly (A) tail, increasing mRNA stability and translation efficiency.

Cy5 mCherry mRNA (5'CAP) is produced through in vitro transcription. By simulating the mRNA processing process in eukaryotes, Cy5 mCherry mRNA (5'CAP) has a 5 'end Cap 1 cap structure, a 3' end poly (A) tail, and Cy5-UTP modification (Cy5-UTP: UTP=3:1 (molar ratio)), which increases the stability and translation efficiency of mRNA.

Cy5 mCherry mRNA with N1-Me-pUTP (5'CAP) is a fluorescent reporter gene commonly used in molecular biology research. Cy5 mCherry mRNA with N1-Me-pUTP (5'CAP) is produced through in vitro transcription. By simulating the mRNA processing process in eukaryotes, it has a 5 'end Cap 1 cap structure, a 3' end poly (A) tail, Cy5-UTP modification, and N1-Me-pUTP modification (Cy5-UTP: N1-Me-pUTP=3:1 (molar ratio)), which increases the stability and translation efficiency of mRNA.

Cy5 OVA mRNA (5'CAP) is produced through in vitro transcription, which simulates the mRNA processing process in eukaryotes. It has a 5 'end Cap 1 cap structure, a 3' end poly (A) tail, and Cy5-UTP modification (Cy5-UTP: UTP=3:1 (molar ratio)), increasing the stability and translation efficiency of mRNA^[1].

Cy5 OVA mRNA with N1-Me-pUTP (5'CAP) is produced through in vitro transcription. By simulating the mRNA processing in eukaryotes, it has a 5 'end Cap 1 cap structure, a 3' end poly (A) tail, Cy5-UTP modification, and N1-Me-pUTP modification (Cy5-UTP: N1-Me-pUTP=3:1 (molar ratio)), which increases the stability and translation efficiency of mRNA.

eGFP mRNA with N1-Me-pUTP (5'CAP) is a labeled green fluorescent protein mRNA produced by in vitro transcription, has a Cap 1 cap structure and a poly(A) tail, and contains N1-Me-pUTP modification.

eGFP mRNA (5'CAP) is a green fluorescent protein mRNA produced by in vitro transcription and has a Cap 1 cap structure and a poly(A) tail.

Fluc mRNA with N1-Me-pUTP (5'CAP) is labeled luciferase mRNA produced by in vitro transcription, has a Cap 1 cap structure and a poly(A) tail, and contains N1-Me-pUTP modification.

Fluc mRNA (5'CAP) is labeled luciferase mRNA produced by in vitro transcription and has a Cap 1 cap structure and a poly(A) tail.

Fluc-eGFP mRNA(5'CAP) is labeled luciferase mRNA produced by in vitro transcription, has a Cap 1 cap structure and a poly(A) tail.

mCherry mRNA (5'CAP) is a commonly used fluorescent reporter gene in molecular biology research, with a Cap 1 cap structure and a poly(A) tail.

mCherry mRNA with N1-Me-pUTP is a commonly used fluorescent reporter gene in molecular biology research, with a Cap 1 cap structure and a poly(A) tail, and contains N1-Me-pUTP modification.

TRIzol LS Reagent is a reagent specially used to extract high-quality RNA from liquid samples (such as bacteria, viruses, yeast, cells, blood, tissue suspension).

TRIzol NC Reagent is a total RNA extraction reagent that without using chloroform, and is widely suitable for cultured cells, animal tissues, and plant tissues.